Press release, Helsinki, 15 August 2019 at 3.00 pm (EET)
Nexstim Plc (NXTMH:HEX, NXTMS:STO) - the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD) - announces that it has expanded its presence in Florida with Neuro Wellness TMS Centers of America.
Neuro Wellness TMS Centers of America is a TMS therapy provider in Florida. The first Nexstim NBT® system with unique SmartFocus® technology was installed at the Neuro Wellness’ clinic in Coral Springs to serve the patients of south Florida suffering from depression.
Matt Lahn, President of Neuro Wellness Centers of America, commented: “There is an incredible number of patients in Florida and the surrounding areas suffering from major depressive disorder. It is our goal to educate as many of them as possible and we look to provide access to state-of-the-art therapy and treatments. By adding new locations to Neuro Wellness Centers of America we make this a reality for more patients and having included SmartFocus® TMS along with our offerings, we give them the most clinically relevant treatments. We have found the Nexstim system to be critical not only in treating these patients but also in helping us to grow our business.”
Martin Jamieson, Chairman and CEO of Nexstim Plc, said: “We are happy that Neuro Wellness TMS Centers of America, a major TMS therapy provider in Florida area, has seen the potential of our SmartFocus® TMS technology. Our unique business model helps to grow both our customer’s business as well as ours - this cooperation with Neuro Wellness TMS Centers of America is a great example of that."
Further information is available on the website www.nexstim.com or by contacting:
Nexstim
Martin Jamieson, Chairman and CEO
+44 771 516 3942
martin.jamieson@nexstim.com
About Nexstim Plc
Nexstim is a medical technology company focused on the development and commercialization of its world leading SmartFocus® TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company’s proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.
Nexstim’s NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.